{
  "schema_version": "0.4",
  "ir_kind": "hl",
  "metadata": {
    "title": "Cytomix treatment protocol",
    "source": {
      "type": "paper",
      "id": "s41467-025-68247-6.pdf"
    }
  },
  "resources": {
    "materials": [],
    "containers": [],
    "equipment": [],
    "samples": [],
    "data": []
  },
  "protocol": {
    "steps": [
      {
        "id": "s1",
        "op": "annotate",
        "inputs": [],
        "outputs": [],
        "params": {},
        "annotations": {
          "description": "For cytomix treatment, human recombinant TNFɑ (R&D Systems), IFNɣ (R&D systems), and IL-1β (PeproTech) were dissolved in organoid media (without EGF or Nicotinamide) for 8 hours"
        }
      },
      {
        "id": "s2",
        "op": "annotate",
        "inputs": [],
        "outputs": [],
        "params": {},
        "annotations": {
          "description": "after which organoids were washed twice with Advanced DMEM/F12"
        }
      },
      {
        "id": "s3",
        "op": "annotate",
        "inputs": [],
        "outputs": [],
        "params": {},
        "annotations": {
          "description": "and then replaced with organoid media"
        }
      }
    ],
    "start_step_id": "s1",
    "edges": [
      {
        "from": "s1",
        "to": "s2"
      },
      {
        "from": "s2",
        "to": "s3"
      }
    ],
    "detail_level": 0
  }
}